Rikke holds a PhD in biochemisty and molecular biology from Aarhus University and has worked with antibody discovery for almost ten years at Novo Nordisk, where she was a key contributor in developing a monoclonal antibody (mAb) production platform. Rikke also has significant entrepreneurial experience, most recent as the CEO and Founder of BEO Therapeutics in Switzerland.